End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 24 | Pfizer Keeps Q2 Dividend at $0.42 a Share, Payable June 14 to Holders of Record May 10 | MT |
Apr. 23 | Edwards Lifesciences Corporation: The story continues |
Financials (USD)
Sales 2024 * | 59.96B | Sales 2025 * | 62.57B | Capitalization | 149B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B | Net income 2025 * | 9.29B | EV / Sales 2024 * | 3.27 x |
Net Debt 2024 * | 47.04B | Net Debt 2025 * | 41.91B | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
14
x | Employees | - |
Yield 2024 * |
6.46% | Yield 2025 * |
6.62% | Free-Float | 59.09% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
1st Jan change | Capi. | |
---|---|---|
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-5.21% | 147B |